Dolutegravir - ClinicalTrials.gov

Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants

This review examined the virologic efficiency and safety of three ARV regimens in pregnant women living with HIV: dolutegravir plus emtricitabine/tenofovir alafenamide, DTG plus empiritabine/tenofovir disoproxil fumarate, and efavirenz/tenofovir disoproxil fumarate. During pregnancy, women completed research visits at the beginning of the study and every four weeks. Breast milk collection from mothers of breastfed, hair and urine testing, ultrasound images, pregnancy testing, condomation, and, for a subset of participants, dual energy x-ray absorptiometry scans for mothers and infants were also included in the study visits.

Source link: https://clinicaltrials.gov/ct2/show/NCT03048422

A Phase III, Randomised, Double-blind, Multicentre, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naïve Adults

Through Week 148, the study will compare the non-improving antiviral activities of DTG+3TC regimen to that of DTG+ TDF/FTC FDC, which will also assess long-term antiviral activity, tolerability, and safety of DTG+3TC regimens.

Source link: https://clinicaltrials.gov/ct2/show/NCT02831764

A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults

Through Week 148, the aim of the research is to compare the non-inferior antiviral activity of DTG plus 3TC regimen to that of DTG plus TDF/FTC FDC, and it will help to determine the long-term antiviral activity, tolerability, and safety of DTG plus 3TC regimen.

Source link: https://clinicaltrials.gov/ct2/show/NCT02831673

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions